“RECENT UPDATE ON PYRIMIDINE DERIVATIVES AS POTENTIAL DPP-IV INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS”. Journal of Pharmaceutical Negative Results, Dec. 2022, pp. 5734-43, https://doi.org/10.47750/pnr.2022.13.S07.696.